Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that 5α-reductase inhibitors significantly increase the risk of erectile dysfunction and hypoactive sexual desire in men with benign prostatic hyperplasia, compared to placebo.

This study found that parents identified with cryptic NCCAH through genetic testing are mostly asymptomatic but may experience temporary female infertility and require glucocorticoid stress coverage in specific circumstances.

This review discusses the genetics and variable phenotypic expression of nonclassic congenital adrenal hyperplasia, and reports no new clinical results; the authors call for further research on long-term health impacts and treatment strategies.

This review discusses clinical, hormonal, and genetic aspects of nonclassic adrenal hyperplasia and reports no new findings; the condition is highlighted as a potential cause of premature adrenarche and other symptoms in young people.

This review covers the pathophysiology, diagnosis, and treatment of nonclassic congenital adrenal hyperplasia due to P450c21, but it reports no new clinical results.

This study found that men aged 50 and older with clinical benign prostatic hyperplasia have a significantly higher prevalence of metabolic syndrome than those without the condition in the UK primary care population.

This study found that 5-α reductase inhibitors do not significantly increase the risk of erectile dysfunction in men with benign prostatic hyperplasia or alopecia, although duration of benign prostatic hyperplasia may elevate risk.

This review discusses the pathophysiology, genetics, and management of nonclassic congenital adrenal hyperplasia, noting subfertility and hormonal issues without providing new clinical results.

This study found that diagnosing nonclassic congenital adrenal hyperplasia in women based solely on serum 17OHP measurements can lead to false positives, suggesting the need for urinary steroid profiles and genetic testing for confirmation.

This study found that Ganoderma lucidum extracts reduced prostate enlargement and improved symptoms in testosterone-treated rats, suggesting potential benefits for managing benign prostatic hyperplasia.

This study suggests that the use of finasteride for benign prostate hyperplasia may increase the risk of osteoporosis diagnosis, particularly at higher doses.

This review analyzes the potential mechanisms by which SARS-CoV-2 may exacerbate symptoms of benign prostatic hyperplasia and suggests a connection via ACE2 and androgen receptor pathways; it reports no new clinical results.

This review summarized existing research on finasteride and erectile dysfunction, finding a correlation between finasteride use for benign prostatic hyperplasia and ED, but not strongly for male androgenetic alopecia.

This study found that in patients with nonclassical 21-hydroxylase deficiency, genotypes do not reliably predict the severity of hyperandrogenic symptoms, suggesting other genetic factors may influence the phenotype.

Researchers observed that dutasteride and finasteride caused structural changes in the penises of both control and hypertensive rats, with dutasteride having a more pronounced effect on the corpus cavernosum.

This study found that young women with nonclassic congenital adrenal hyperplasia had impaired sexual function and mild depressive symptoms compared to healthy women.

In this study, researchers found that androgen receptor gene polymorphism is associated with higher androgenetic alopecia grades and PSA levels in men with benign prostatic hyperplasia, but not with prostate cancer.

In this study, children with classical congenital adrenal hyperplasia were found to have increased epicardial fat thickness, which was associated with subclinical atherosclerosis markers and left ventricular dysfunction, especially in poorly controlled cases.

This study found that patients with androgenetic alopecia had a higher incidence of metabolic syndrome and benign prostatic hyperplasia compared to those without the condition.

This study found that Caesalpinia bonduc seed extracts significantly reduced prostate weight and improved prostate tissue morphology in Wistar rats with testosterone-induced benign prostatic hyperplasia.

This study suggests that using both finasteride and dutasteride may increase the risk of acute coronary syndrome in patients with benign prostate hyperplasia.

This study found that premenopausal women with non-classic congenital adrenal hyperplasia may have increased cardiometabolic risk compared to healthy women.

This cohort study using real-world data found no significant difference in the risk of developing prostate cancer between finasteride and dutasteride among patients with benign prostatic hyperplasia, despite previous suggestions that dutasteride might be more effective.

This case report describes a 46-year-old Italian woman with congenital adrenal hyperplasia who experienced significant improvements in physical and psychological health after receiving a delayed diagnosis and subsequent treatment.

This case report documents a 59-year-old man in Taiwan who developed breast cancer while undergoing finasteride therapy for benign prostate hyperplasia, marking a rare side effect.

In this study, a pH-responsive microneedle patch was developed, showing potential in rat models for treating spinal cord injuries by reducing inflammation, promoting nerve regeneration, and supporting neurogenesis, which contributed to improved motor and neurological recovery.

This review details contemporary medical management options for benign prostatic hyperplasia, highlighting the expanding role of phosphodiesterase-5 inhibitors and beta-3 agonists, but reports no new clinical findings.

This case report describes a 6 1/2-year-old girl with significant height growth and early pubic hair development.

In this study, researchers observed that Cuscuta reflexa extract mitigated inflammation and oxidative stress in testosterone-induced benign prostatic hypertrophy in Wistar rats, suggesting its potential as an adjunctive therapy for BPH.

This case report highlights a rare instance of postmenopausal virilization in a 71-year-old woman due to coexisting ovarian hilus cell hyperplasia and a Sertoli-Leydig cell tumor.